Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model

International Journal of Molecular Medicine

Volumn 31, Issue 2, 2013, Pages 377-385

  Wang, Huiping ^a   Wei, Fang ^a   Li, Huiming ^a   Ji, Xunda ^a   Li, Shuxia ^b   Chen, Xiafang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

E1A; E1B; E2F1; Endostatin; Human retinoblastoma; Oncolytic adenovirus; Replication defective adenovirus

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; E1B PROTEIN; ENDOSTATIN; ENHANCED GREEN FLUORESCENT PROTEIN; ONCOLYTIC ADENOVIRUS; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG EFFICACY; EMBRYO; GENE CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RETINOBLASTOMA; STEREOMICROSCOPY; TUMOR CELL DESTRUCTION; TUMOR MODEL; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; E2F1 TRANSCRIPTION FACTOR; ENDOSTATINS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; RETINA; RETINAL NEOPLASMS; RETINOBLASTOMA; TELOMERASE;

EID: 84873102785     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1197     Document Type: Article

References (38)

1. Lohmann DR and Gallie BL: Retinoblastoma: revisiting the model prototype of inherited cancer. Am J Med Genet C Semin Med Genet 129C: 23-28, 2004.
2. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F and Terenziani M; EUROCARE Working Group: Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 23: 3742-3751, 2005.
3. Abramson DH, Beaverson K, Sangani P, et al: Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics 112: 1248-1255, 2003.
4. Balmer A, Zografos L and Munier F: Diagnosis and current management of retinoblastoma. Oncogene 25: 5341-5349, 2006.
5. Sun A, Bagella L, Tutton S, Romano G and Giordano A: From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem 102: 1400-1404, 2007.
6. Sabado Alvarez C: Molecular biology of retinoblastoma. Clin Transl Oncol 10: 389-394, 2008.
7. Jia RB, Zhang P, Zhou YX, et al: VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 39: 108-115, 2007.
8. Chevez-Barrios P, Chintagumpala M, Mieler W, et al: Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 23: 7927-7935, 2005.
9. Kirn D, Martuza RL and Zwiebel J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787, 2001.
10. Kruyt FA and Curiel DT: Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 13: 485-495, 2002.
11. Ramachandra M, Rahman A, Zou A, et al: Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 19: 1035-1041, 2001.
12. Fuerer C and Iggo R: Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther 9: 270-281, 2002.
13. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
14. Strauss M, Lukas J and Bartek J: Unrestricted cell cycling and cancer. Nat Med 1: 1245-1246, 1995.
15. Lu K, Shih C and Teicher BA: Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer Chemother Pharmacol 46: 293-304, 2000.
16. Jakubczak JL, Ryan P, Gorziglia M, et al: An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 63: 1490-1499, 2003.
17. Ries SJ and Brandts CH: Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 9: 759-768, 2004.
18. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
19. Querido E, Marcellus RC, Lai A, et al: Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J Virol 71: 3788-3798, 1997.
20. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ and Bos JL: The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16: 349-357, 1998.
21. Cuconati A, Degenhardt K, Sundararajan R, Anschel A and White E: Bak and Bax function to limit adenovirus replication through apoptosis induction. J Virol 76: 4547-4558, 2002.
22. Farrow SN, White JH, Martinou I, et al: Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374: 731-733, 1995.
23. Hobom U and Dobbelstein M: E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol 78: 7685-7697, 2004.
24. Rao XM, Tseng MT, Zheng X, et al: E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther 11: 585-593, 2004.
25. Rao XM, Zheng X, Waigel S, Zacharias W, McMasters KM and Zhou HS: Gene expression profiles of normal human lung cells affected by adenoviral E1B. Virology 350: 418-428, 2006.
26. Doloff JC, Waxman DJ and Jounaidi Y: Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther 19: 1383-1400, 2008.
27. Ji X, Zhang J, Cheng L, et al: Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res 89: 193-199, 2009.
28. Xu H, Wang C, Zhu H, Liu S, Xu X and Jiang Y: Characteristics of an established retinoblastoma cell line HXO-Rb44. Yan Ke Xue Bao 11: 16-21, 1995.
29. White E: Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 20: 7836-7846, 2001.
30. Subramanian T, Vijayalingam S and Chinnadurai G: Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 80: 2000-2012, 2006.
31. White E: Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ 13: 1371-1377, 2006.
32. Cross JR, Postigo A, Blight K and Downward J: Viral pro-survival proteins block separate stages in Bax activation but changes in mitochondrial ultrastructure still occur. Cell Death Differ 15: 997-1008, 2008.
33. Yoon AR, Kim JH, Lee YS, et al: Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 17: 379-390, 2006.
34. Lomonosova E, Subramanian T and Chinnadurai G: Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K. Oncogene 24: 6796-6808, 2005.
35. Matsushita T, Okada T, Inaba T, Mizukami H, Ozawa K and Colosi P: The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production. J Gen Virol 85: 2209-2214, 2004.
36. Polster BM, Pevsner J and Hardwick JM: Viral Bcl-2 homologs and their role in virus replication and associated diseases. Biochim Biophys Acta 1644: 211-227, 2004.
37. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP and Amin KM: An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 62: 3438-3447, 2002.
38. Rohmer S, Quirin C, Hesse A, et al: Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. Virology 395: 243-254, 2009.